Why the study?
Despite oral antiplatelet therapy, atherothrombotic events recur after PCI, and residual platelet activity or antiplatelet resistance may underlie these adverse outcomes.
What is the prevalence and what are the predictors of aspirin and clopidogrel resistance in patients undergoing elective PCI for stable CAD?
What is the prevalence and what are the predictors of aspirin and clopidogrel resistance in patients undergoing elective PCI for stable CAD?
This study aims to determine the prevalence and predictors of aspirin and clopidogrel resistance in patients undergoing elective PCI for stable CAD.
Answers are grounded in this paper and cite their sources.
Provides prevalence and predictor data in elective PCI; leaves open whether resistance testing should guide therapy in stable CAD.
Objectives: Dual antiplatelet therapy with aspirin and a P2Y12 inhibitor is the mainstay of antithrombotic therapy after myocardial infarction and percutaneous coronary interventions (PCI). Despite chronic oral antiplatelet therapy, many atherothrombotic events continue to occur. Several reports in the literature have shown possible relationships between residual platelet activity and clinical outcomes, raising the possibility that "resistance" to oral antiplatelet therapy may underlie such adverse events. In this study, we aimed to determine the prevalence of aspirin and clopidogrel resistance, and related factors. We also aimed to identify the predictors of reduced antiplatelet response among patients undergoing elective PCI for stable coronary artery disease (CAD).
No takes yet. Share an insight, caveat, or question.
Karabulut et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: